Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Subscribe To Our Newsletter & Stay Updated
